Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
testosterone undecanoate + phosphodiesterase type 5 inhibitor
- Development stage
- Unknown
- Lead developer
- Hospital Santa Fe
- Modality
- Small Molecules
- Administration
- Intramuscular, Oral
01
Overview
The combination of **testosterone undecanoate** and a **phosphodiesterase type 5 (PDE-5) inhibitor** is a therapeutic regimen evaluated for the treatment of male hypogonadism and associated erectile dysfunction (ED). Testosterone undecanoate is a long-acting ester of the natural androgen testosterone, administered via intramuscular injection to restore physiological testosterone levels, which are critical for maintaining sexual desire and the structural integrity of erectile tissues. PDE-5 inhibitors work by inhibiting the degradation of cyclic guanosine monophosphate (cGMP) in the corpus cavernosum, thereby enhancing the vasodilatory response to nitric oxide. This combination is particularly targeted at hypogonadal men who show an inadequate response to PDE-5 inhibitor monotherapy, leveraging the synergistic effects of hormonal replacement and targeted enzymatic inhibition to improve erectile function.
- Other names
- Nebidolocaltestosterone undecanoate + PDE-5
02
Targets
PDE5 (Phosphodiesterase 5A)AR (Adrenergic receptors)
Beyond the preview
Go deeper on testosterone undecanoate + phosphodiesterase type 5 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on testosterone undecanoate + phosphodiesterase type 5 inhibitor.